^
Association details:
| Biomarker: | STK11 deletion + KRAS mutation |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
EP08.01-043 - Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced Non-small Cell Lung Cancer (NSCLC)
Published date:
07/12/2022
Excerpt:
In this multicenter retrospective analysis, clinicopathologic and genomic data were collected from patients with metastatic NSCLC....A total of 1200 patients treated with first-line pembrolizumab in combination with platinum-doublet chemotherapy were identified....KRAS mutations were detected in 271 cases, and deleterious STK11 and KEAP1 mutations were found in 182 and 184 cases, respectively....STK11 and KEAP1 mutations were associated with significantly worse mPFS (STK11 HR:1.93, P<0.001; KEAP1 HR:1.79, P<0.001) and mOS (STK11 HR:1.72, P<0.001; KEAP1 HR:1.75, P<0.001) to chemoimmunotherapy among KRAS mutant cases...deleterious STK11 and KEAP1 mutations impact chemoimmunotherapy efficacy similarly among KRAS mutant NSCLCs...
Secondary therapy:
Chemotherapy
